Korean J Urol.  1995 Dec;36(12):1315-1322.

Immunohistochemical Expression of ras p21 and HER-2/neu Oncoproteins in Transitional Cell Carcinoma of the Bladder

Affiliations
  • 1Department of Urology, Inha University, College of Medicine, Sungnam, Korea.
  • 2Department of Urology, Hanyang University, College of Medicine, Seoul, Korea.

Abstract

Using specific monoclonal antibodies to the ras and HER-2/neu oncoprotein, a total of 8 normal urothelium and 58 transitional cell carcinoma(TCC) of the urinary bladder were stained immunohistochemically to investigate the possible roles of the oncogenes in the development of bladder TCC and their implications. Of the 52 bladder TCC specimens which contained the outer layer in the sections, 51 tumors showed the expression of the ras p21 in the outer layer. 56 of 58 bladder TCC specimens showed the expression of ras p21 in the intermediate and basal layers. The staining intensity in whole layers was relatively higher than that of the normal urothelium. The staining intensity in outer layer was not correlated with the tumor grade and invasiveness, while in intermediate and basal layers significantly correlated. HER-2/neu expression occurred in 22 (38%) of 58 TCC, whereas no normal urothelial cells were reactive for HER-2/neu. HER-2/neu expression rate was significantly correlated with the tumor grade and invasiveness. These findings suggest that ras and HER-2/neu oncogenes may play a crucial role in the development of bladder TCC and that immunohistochemical characteristics of these oncoproteins may give a additional prognostic information in the patients with bladder TCC.

Keyword

Transitional cell carcinoma; Histochemical reaction; ras p21 HER-2/neu oncoprotein

MeSH Terms

Antibodies, Monoclonal
Carcinoma, Transitional Cell*
Humans
Oncogene Proteins*
Oncogenes
Urinary Bladder*
Urothelium
Antibodies, Monoclonal
Oncogene Proteins
Full Text Links
  • KJU
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr